Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | TPMT | P51580 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.47 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30469876 | 1.00 | TSHR (0.50) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1164664 | 0.85 | ALOX15 (0.51) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL29521706 | 0.84 | TSHR (0.70) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL184025 | 0.84 | TSHR (0.70) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL8590467 | 0.82 | TSHR (0.68) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10885938 | 0.82 | TSHR (0.52) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL503429 | 0.82 | CA12 (0.71) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL801748 | 0.82 | LMNA (0.57) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL31406172 | 0.82 | CA12 (0.71) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL21943579 | 0.81 | ACHE (0.56) | TSHRRAB9AHTTPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119269665-A | Method for detecting menthol content based on rapid and catalyst-free pre-column derivative liquid chromatography | 广东超聚和生物科技有限公司 | 2025-01-07 | — | — | CN | claimed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4616906-A2 | BENZO[A]PHENANTHRIDINE DERIVATIVES AS YAP/TAZ INHIBITORS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-119269665-A | Method for detecting menthol content based on rapid and catalyst-free pre-column derivative liquid chromatography | 广东超聚和生物科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20060020146-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | RHEOGENE, INC. | 2006-01-26 | — | — | US | disclosed |
| EP-1601642-A2 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene, Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004078924-A2 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| EP-1244655-B1 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2004-02-18 | — | — | EP | disclosed |
| US-6620837-B1 | 1-Benzothiophene derivatives | ELI LILLY AND COMPANY | 2003-09-16 | — | — | US | disclosed |
| EP-1244655-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001036414-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2001-05-25 | — | — | WO | disclosed |
| EP-0083228-B1 | PHARMACEUTICALLY ACTIVE PHENYLCARBOXYLIC ACID DERIVATIVES | ICI AMERICAS INC. (US) | 1985-05-15 | — | — | EP | disclosed |
| US-4499299-A | Pharmaceutically active phenylcarboxylic acid derivatives | ICI AMERICAS INC. (US) | 1985-02-12 | — | — | US | disclosed |
| EP-0083228-A1 | Pharmaceutically active phenylcarboxylic acid derivatives | ICI AMERICAS INC. (US) | 1983-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020146-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, NR5A1, NR5A2 | TSHR 501/4885CYP1A2 482/4885CYP3A4 1320/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TSHR 728/4885CYP1A2 50/4885CYP3A4 63/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | TSHR 728/4885CYP1A2 50/4885CYP3A4 63/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | TSHR 728/4885CYP1A2 50/4885CYP3A4 63/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TSHR 728/4885CYP1A2 50/4885CYP3A4 63/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | TSHR 246/4885CYP1A2 152/4885CYP3A4 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.